Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Change in Accured Expenses for 16 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 41.46% year-over-year to $5.2 million, compared with a TTM value of $24.2 million through Dec 2025, down 55.13%, and an annual FY2025 reading of $24.2 million, down 55.13% over the prior year.
  • Change in Accured Expenses was $5.2 million for Q4 2025 at Catalyst Pharmaceuticals, down from $13.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $20.0 million in Q3 2024 and bottomed at -$7.0 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is $5.3 million, with a median of $5.8 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 316.77% in 2023, then surged 449.88% in 2024.
  • Year by year, Change in Accured Expenses stood at $6.4 million in 2021, then skyrocketed by 78.78% to $11.5 million in 2022, then dropped by 28.82% to $8.2 million in 2023, then increased by 8.67% to $8.9 million in 2024, then plummeted by 41.46% to $5.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CPRX at $5.2 million in Q4 2025, $13.2 million in Q3 2025, and $8.3 million in Q2 2025.